<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02455895</url>
  </required_header>
  <id_info>
    <org_study_id>CM-01-14</org_study_id>
    <nct_id>NCT02455895</nct_id>
  </id_info>
  <brief_title>Efficacy of iLid Cleanser (Avenova) Versus Vehicle on Ocular Skin Flora</brief_title>
  <official_title>A Multicenter Randomized, Double-Masked Study Comparing the Efficacy of Novabay iLid Cleanser Versus Vehicle on Ocular Skin Flora</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NovaBay Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NovaBay Pharmaceuticals, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is designed to evaluate the effect of Novabay iLid Cleanser, as compared to its&#xD;
      Vehicle, on the ocular skin flora.&#xD;
&#xD;
      In the pre-randomization phase, subjects will receive a single application of open-label&#xD;
      NovaBay iLid Cleanser.&#xD;
&#xD;
      In the randomization phase of Stages 1 and 2, subjects will self-treat with masked&#xD;
      Investigational Product twice daily for ten (10) days.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an adaptive design, randomized, double-masked, vehicle-controlled, multicenter,&#xD;
      parallel group study with two treatment arms: NovaBay iLid Cleanser (&quot;Cleanser&quot;) and Cleanser&#xD;
      Vehicle (&quot;Vehicle&quot;).&#xD;
&#xD;
      The study will be conducted in two Stages, each preceded by a pre-randomization phase.&#xD;
      Randomization of Cleanser:Vehicle will be 1:1 and 2:1 in Stages 1 and 2 respectively.&#xD;
&#xD;
      In the pre-randomization phase for Stages 1 and 2, subjects who meet all inclusion and no&#xD;
      exclusion criteria will be evaluated by clinical examination at a single visit prior to&#xD;
      having ocular skin specimens taken before and after treatment with open-label Cleanser.&#xD;
&#xD;
      In the randomization phase for both Stages 1 and 2, subjects who meet all inclusion and no&#xD;
      exclusion criteria will be randomized and evaluated at three visits:&#xD;
&#xD;
        -  Visit 1: Screening, Day 1&#xD;
&#xD;
        -  Visit 2: Day 11 (+2) End of Treatment (EOT)&#xD;
&#xD;
        -  Visit 3: Day 18 (±2) Post Treatment Evaluation/Exit Subjects will have ocular skin&#xD;
           specimens taken at Visit 1, Day 1. The specimens will be collected before and 20 minutes&#xD;
           after the first application of the study Investigational Product performed by study&#xD;
           personnel.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>May 2015</start_date>
  <completion_date type="Anticipated">May 2016</completion_date>
  <primary_completion_date type="Anticipated">January 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Microbiological efficacy</measure>
    <time_frame>20 minutes after application of test article</time_frame>
    <description>Quantitative assessment of numbers of recoverable bacteria before versus after application of test article</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Ocular Signs</measure>
    <time_frame>Assessed on Visit 1(Day 1), Visit 2 (Day 11) and Visit 3 (Day 18)</time_frame>
    <description>lid erythema, lid swelling, lid crusting and debris on lashes, bulbar and palpebral conjunctival injection, and meibomian gland secretions (after expression)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Sebaceous Gland Diseases</condition>
  <condition>Blepharitis</condition>
  <arm_group>
    <arm_group_label>iLid Cleanser (Avenova)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>iLid Cleanser - applied 2 times per day for 10 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>iLid Cleanser Vehicle</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>iLid Cleanser Vehicle - applied 2 times per day for 10 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>iLid Cleanser</intervention_name>
    <description>Application of iLid Cleanser to reduce bacterial load on the lid and lash margins</description>
    <arm_group_label>iLid Cleanser (Avenova)</arm_group_label>
    <arm_group_label>iLid Cleanser Vehicle</arm_group_label>
    <other_name>Avenova</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, of any race, at least 6 years of age.&#xD;
&#xD;
          -  Must be eligible for a recommendation to use eye lid cleansing/scrubs for:&#xD;
&#xD;
               -  Signs of acute or chronic blepharitis, such as eye lid debris (sleeves,&#xD;
                  collorates, flakes, crusting) requiring eye lid cleansing/scrubs, and/or&#xD;
&#xD;
               -  Signs consistent with mild, moderate, or severe meibomian gland disease (MGD)&#xD;
                  such as dilated and blocked glands with inspissated secretions sluggish or&#xD;
                  stagnant upon expression.&#xD;
&#xD;
          -  Must be able to read, understand and sign an informed consent form that has been&#xD;
             approved by an Institutional Review Board/Ethics Committee. If subject is less than 18&#xD;
             years of age, the informed consent must be signed and dated by subject's legally&#xD;
             authorized representative (parent or guardian). Assent to participate should also be&#xD;
             obtained from subjects under 18 years of age if required by local regulation.&#xD;
&#xD;
          -  Must agree to comply with the visit schedule and other requirements of the study. The&#xD;
             parent or guardian must agree to ensure compliance of subjects less than 18 years of&#xD;
             age.&#xD;
&#xD;
          -  Must agree to remove contact lenses, if applicable, for 15 minutes before and after&#xD;
             application of the study Investigational Product.&#xD;
&#xD;
          -  Must agree for the duration of the study to refrain from use of makeup/cosmetic&#xD;
             products used around the eye(s) such as eye liner, mascara, and/or shadow, foundation&#xD;
             or powder. Use of such products is allowed if the eyelid skin area is avoided.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of signs and symptoms of bacterial or allergic conjunctivitis or allergic&#xD;
             dermatitis at the Day 1 Visit.&#xD;
&#xD;
          -  Suspected fungal, viral, Chlamydia or Acanthamoeba infection based on clinical&#xD;
             diagnosis.&#xD;
&#xD;
          -  Visual acuity not correctable to 1.0 LogMAR or better (equivalent to Snellen 20/200)&#xD;
             in either eye using either a Snellen or ETDRS chart.&#xD;
&#xD;
          -  Use of any topical ocular medications including tear substitutes during study&#xD;
             participation.&#xD;
&#xD;
          -  Use of any preserved or non-preserved glaucoma medications during the 14 days prior to&#xD;
             Visit 1 and anticipated use during study participation.&#xD;
&#xD;
          -  Presence of nasolacrimal duct obstruction.&#xD;
&#xD;
          -  Presence of a punctal plug in either eye.&#xD;
&#xD;
          -  Any systemic or ocular disease or disorder, complicating factors or structural&#xD;
             abnormality that would negatively affect the conduct or outcome of the study.&#xD;
&#xD;
          -  Presence of active inflammation and/or active structural change in the cornea, iris or&#xD;
             anterior chamber at the Day 1 visit.&#xD;
&#xD;
          -  Use of any topical ocular or oral antimicrobial agent within the 3 days prior to Day 1&#xD;
             visit.&#xD;
&#xD;
          -  Use of topical ocular corticosteroids or non-steroidal topical ocular&#xD;
             anti-inflammatories (NSAIDs), within 3 days prior to study entry and during the trial.&#xD;
&#xD;
          -  Use of RESTASIS® (Cyclosporine Ophthalmic Emulsion) 0.05%) in either eye during the&#xD;
             trial.&#xD;
&#xD;
          -  Any current immunosuppressive disorder (e.g., HIV positive), or use of&#xD;
             immunosuppressive therapy (including chemotherapy).&#xD;
&#xD;
          -  Participation in any other investigational clinical study within 30 days prior to&#xD;
             study enrollment.&#xD;
&#xD;
          -  Any subject who is on staff at the investigational site or is a family member of staff&#xD;
             personnel.&#xD;
&#xD;
          -  Additionally, the Investigator or Medical Monitor may declare any subject ineligible&#xD;
             for a sound medical reason.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David W. Stroman, Ph.D.</last_name>
    <role>Study Director</role>
    <affiliation>NovaBay Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>David W Stroman, Ph.D.</last_name>
    <phone>510-899-8813</phone>
    <email>dstroman@novabay.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Katy Najafi-Tagol, MD</last_name>
    <phone>415-577-7090</phone>
    <email>knajafi@novabay.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ophthalmic Research Consultants of Arizona</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85032</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Sarich</last_name>
      <phone>602-549-2020</phone>
      <email>sarich.andrea@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Arthur Epstein, OD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Turner Eye Institute</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94577</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Erika Chang</last_name>
      <phone>800-339-2733</phone>
      <email>echang@turnereye.com</email>
    </contact>
    <investigator>
      <last_name>Chirag Patel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>James D. Branch, MD</name>
      <address>
        <city>Winston Salem</city>
        <state>North Carolina</state>
        <zip>27101</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elaine Acosta</last_name>
      <phone>336-721-4711</phone>
      <email>emaeye@hotmail.com</email>
    </contact>
    <investigator>
      <last_name>James Branch, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2015</verification_date>
  <study_first_submitted>May 26, 2015</study_first_submitted>
  <study_first_submitted_qc>May 27, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 28, 2015</study_first_posted>
  <last_update_submitted>May 27, 2015</last_update_submitted>
  <last_update_submitted_qc>May 27, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 28, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Blepharitis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Blepharitis</mesh_term>
    <mesh_term>Sebaceous Gland Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

